An observational study in Hereditary Cancer Syndrome, sponsored by Columbia University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Columbia University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Neoplastic Syndromes, Hereditary with a site in United States — 19 open to participants now, 21 under way, none of them phase 3. Neoplastic Syndromes, Hereditary · United States.
Among the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, this one is the 8th largest by planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2026, is one of 15 observational ones, reaches primary completion later than 6 of the 18 other live ones, and was the 31st registered.
47 studies on the registry are indexed under Neoplastic Syndromes, Hereditary; 26 are open to participants now.
Browse Neoplastic Syndromes, Hereditary studies →19 of the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 21–75 · Women only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
Weill Medical College of Cornell University · Sites in United States
Ages 18–55 · Women only
Shwachman-Diamond Syndrome Alliance Inc · Sites in United States
San Raffaele University · Sites in United States, Italy
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Neoplastic Syndromes, Hereditary studies recruiting now, 11 (55%) set no upper age limit and 6 (30%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 55 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 667 across 24 observational studies indexed under Neoplastic Syndromes, Hereditary.
Median enrollment 588 across the 18 interventional studies, 1,000 across the 15 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 33 have an industry lead sponsor. The 10 most frequent:
Columbia University is the lead sponsor of 1,136 studies on the registry; 194 are open to participants now.
Of its 182 completed or terminated interventional studies of FDA-regulated products, 150 (82%) have results posted.
Columbia University has 2 studies filed under Neoplastic Syndromes, Hereditary — fewer than ten, so there is no comparison to draw.
5 of the studies in Neoplastic Syndromes, Hereditary with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05664867University of Illinois at ChicagoImplementation of Population Cancer Genetic Services in Federally Qualified Health Centers (FQHC) | 2026-12 |
| NCT06096688Weill Medical College of Cornell UniversityDiscovering New Targets for Colorectal and Endometrial Cancer Risk Reduction | 2026-12-31 |
| NCT06654466Nest GenomicsClosing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer | 2027-03 |
| NCT07052266Weill Medical College of Cornell UniversityTrial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening | 2027-06 |
| NCT07053813University of WashingtonApplying Population Management Best Practices to Preventative Genomic Medicine Trial | 2027-07-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 33 studies in Neoplastic Syndromes, Hereditary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators hypothesize that preconception and pregnancy may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal care or preconception care. The goal is to evaluate the acceptability of hereditary cancer testing when offered alongside standard prenatal genetic screening. The study will also explore whether universal screening in this population could support early cancer prevention
In this prospective trial, a clinician in the department of OBGYN will meet with preconception/pregnant patients who are undergoing obstetrical carrier screening (OCS) at Columbia University affiliated OBGYN clinics to review the options for concurrent hereditary cancer screening (HCS). If interested in the study, the patient will be contacted by a study coordinator and offered participation in the study. The patients will have counseling on potential risks and benefits of genetics testing and have OCS performed per standard of care protocols. This consultation will include collection of comprehensive personal and family history to generate a cancer genetic risk assessment. The patient will be counseled based on their cancer genetic risk assessment, whether or not National Comprehensive Cancer Network (NCCN) guidelines for cancer risk assessment are met and the resulting anticipated cost. The patient will be offered additional consultation with a genetic counselor and/or a Natera financial representative if desired for further counseling. If the patient decides to proceed with HCS, the Natera Empower Hereditary Cancer Panel will be drawn at the time of the OCS panel blood draw and sent to Natera for processing. OCS results will be sent separately and reported to the patient based on standard protocols. Patients that have HCS panels sent will be notified of their results by a genetic counselor from Columbia University's Department of OBGYN and standard of care post test counseling/referrals made.
The study team will evaluate patient acceptance of testing and the patient experience, via validated surveys conducted at time of testing. The study team will evaluate if patient sociodemographic characteristic (e.g. age, parity, race, ethnicity, medical history, family history) are associated with patient acceptance of the combined OCS/HSC panel. Patients that elect to undergo HCS panel will also complete the Regret About Healthcare Decisions Survey after receiving their HCS results. Participation in surveys is encouraged but not mandatory. All patient demographics, survey screens and results will be stored in a secure online database maintained by Columbia University's Department of OBGYN. This data will be entered and maintained by study personal at Columbia University. Patients enrolled in the study will be invited to participate in an interview conducted by telephone at times convenient for them. Interviews will be conducted by language-concordant, trained qualitative experts. Interviews will be recorded and transcribed. Participation in the interview is not mandatory.
Patients that completed HCS and had a mutation that resulted in a recommendation for clinical follow up (e.g. BRCA 1/2 mutation with recommendation for breast screening) will be contacted by telephone at 18 months and asked whether they completed the medical follow-up prompted by HCS results. Participation in this follow-up is not mandatory.
Patients receiving expanded carrier screening at OBGYN clinics
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hereditary Cancer screenings testing and Obstetric Cancer Screening
Device: Natera empower comprehensive hereditary cancer panel · Device: Obstetrical carrier screening
Obstetric Cancer screening test only
Device: Obstetrical carrier screening
Natera Empower Comprehensive Hereditary Cancer Panel to screen for hereditary cancers
Obstetrical carrier screening for genetic conditions
Percentage of Participants Who Complete Both HCS and OCS
The percent of patients who complete hereditary cancer screening (HCS) when offered in addition to routine obstetrical carrier screening (OCS) during preconception and obstetrical-related care.
Time frame: Approximately at the end of recruitment, expected at 2 years
Score on Regret About Healthcare Decisions survey
Participant experience with combined HCS and OCS will be assessed using a validated Regret About Healthcare Decisions Survey. The minimum score is 0 (lowest regret) to 100 (highest regret).
Time frame: 2 to 6 months after enrollment
Score on Regret About Healthcare Decisions Survey among pregnant participants
Assessment of participant experience with combined OCS and HCS in pregnant participants using Regret About Healthcare Decisions Survey and qualitative interviews. The minimum score is 0 (lowest regret) to 100 (highest regret).
Time frame: Approximately at the end of recruitment, expected at 2 years
Score on Regret About Healthcare Decisions Survey among nonpregnant participants
Assessment of participant experience with combined OCS and HCS in nonpregnant participants using Regret About Healthcare Decisions Survey and qualitative interviews. The minimum score is 0 (lowest regret) to 100 (highest regret).
Time frame: Approximately at the end of recruitment, expected at 2 years
Hereditary cancer screening results
Number of pathologic variants identified by hereditary cancer screening.
Time frame: Approximately at the end of recruitment, expected at 2 years
Percentage of High-Risk Participants Utilizing Guideline-Based Cancer Mitigation Strategies
Among participants who complete both HCS and OCS and are identified as being at elevated cancer risk, this measure captures the percentage who undergo one or more guideline-based cancer mitigation strategies, such as mammogram, breast MRI, or colonoscopy.
Time frame: 18 months after enrollment
Percentage of Participants Who Complete Both HCS and OCS during pregnancy
The percent of patients who complete hereditary cancer screening (HCS) when offered in addition to routine obstetrical carrier screening (OCS) while pregnant.
Time frame: Approximately at the end of recruitment, expected at 2 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neoplastic Syndromes, Hereditary →